Archive...
Commentary

Rucaparib: A New Lease of Life for Ovarian Cancer Patients

Sachdeva S*, Rabbani TK and Shujauddin
High grade epithelial ovarian cancer, along with fallopian tube and primary peritoneal cancers are generally responsive (partially or completely) to platinum based chemotherapy [1]. Significant scientific evidence has proven Rucaparib to be of substantial promise as monotherapy for maintenance of ovarian cancer patients regardless of genetic mutation [2]....

Review Article

Health Benefits of Plant-Derived Bioactive Secondary Metabolites as Dietary Constituents

Aryadeep Roychoudhury* and Rituparna Bhowmik
Plants are one of the most important sources of human nutrition and they also act as store house of important pharmaceuticals. Plant-derived bioactive compounds have long been used to treat diseases in traditional medicine. Plant biotechnology provides a blooming opportunity for improving the bioactive compounds in our food. This coupled with the emergence of concepts like nutritional therapy and phytotherapy makes us curious about understanding the health benefits of the bioactive compounds in our food....

Letter to Editor

Is it Possible to Prevent Covid-19 by ACE Inhibitors?

Bozorgnia A, Gharibzadeh S and Bozorgnia M*
Outbreaks of emerging infectious diseases continue to challenge human health. The reported incidence of emerging and re-emerging zoonotic disease is increasing in many parts of the world [1]. In December of 2019, a novel coronavirus (SARS-CoV-2) crossed species barriers to infect humans [2] and was effectively transmitted from person to person, leading to a pneumonia outbreak first reported in Wuhan, China [3-5]. This virus causes coronavirus disease-19 (COVID-19) with...

Review Article

Gout and Rheumatoid Arthritis: Available Options for Pharmacotherapy. Overview of World Data

Wisniewski D and Uzar I*
Due to adverse effects, old-age uricosuric medications have been withdrawn only to assisted treatment of gout. Their place was taken by Xanthine Oxidase (XOI) inhibitors as the first-choice medication. Although they are easier to monitor and free from many side effects, they have a limited spectrum of associations. New-generation uricosuric medications have been included in combination therapy with XOI. They can also be used alone in the case of patients with XOI...

  1